Skip to main content

Abbott Will Manufacture Human Thrombin for Zymogenetics

NEW YORK, Oct. 2 (GenomeWeb News) - Zymogenetics today said that Abbott Laboratories will manufacture its recombinant human trombin.


ZymoGenetics, which is developing rhThrombin as an alternative to bovine plasma-derived thrombin for use as a topical hemostat, expects to market the product at the end of 2006, a company spokeswoman told GenomeWeb News.

Plasma-derived thrombin has been used as a hemostatic agent for more than 30 years, and is applied topically to surgical incisions, sutures, and burn, according to Zymogenetics. Bovine thrombin is currently the only form of thrombin that is sold in the United Statesas a stand-alone product for the treatment of surgical bleeding, the company said.


"Recombinant coagulation proteins have so far been accepted by the medical community as safe alternatives to plasma-derived proteins, as demonstrated by the rapid acceptance of recombinant forms of coagulation Factor VIII and Factor IX," Zymogenetics said.


Zymogenetics is a Seattle-based spin-off of Novo Nordisk.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.